Camurus AB (publ) (CAMRF)
USD 50.97
(0.0%)
USD 50.97
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 414.81 Million SEK | 33.46% |
| 2022 | 310.81 Million SEK | 33.4% |
| 2021 | 232.98 Million SEK | 18.47% |
| 2020 | 196.65 Million SEK | 40.06% |
| 2019 | 140.41 Million SEK | 24.92% |
| 2018 | 112.4 Million SEK | 23.61% |
| 2017 | 90.93 Million SEK | 20.67% |
| 2016 | 75.35 Million SEK | -57.13% |
| 2015 | 175.79 Million SEK | 108.75% |
| 2014 | 84.21 Million SEK | 36.69% |
| 2013 | 61.6 Million SEK | 258.3% |
| 2012 | 17.19 Million SEK | -77.46% |
| 2011 | 76.3 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 415.06 Million SEK | 0.06% |
| 2024 Q2 | 503.72 Million SEK | 21.36% |
| 2023 Q4 | 414.81 Million SEK | 17.4% |
| 2023 FY | 414.81 Million SEK | 33.46% |
| 2023 Q1 | 288.58 Million SEK | -7.15% |
| 2023 Q2 | 391.67 Million SEK | 35.72% |
| 2023 Q3 | 353.35 Million SEK | -9.79% |
| 2022 Q1 | 238.9 Million SEK | 2.54% |
| 2022 FY | 310.81 Million SEK | 33.4% |
| 2022 Q3 | 265.1 Million SEK | 8.04% |
| 2022 Q4 | 310.81 Million SEK | 17.24% |
| 2022 Q2 | 245.37 Million SEK | 2.71% |
| 2021 Q4 | 232.98 Million SEK | 6.61% |
| 2021 Q3 | 218.53 Million SEK | -3.32% |
| 2021 FY | 232.98 Million SEK | 18.47% |
| 2021 Q1 | 202.02 Million SEK | 2.73% |
| 2021 Q2 | 226.05 Million SEK | 11.89% |
| 2020 Q3 | 165.96 Million SEK | -4.49% |
| 2020 FY | 196.65 Million SEK | 40.06% |
| 2020 Q2 | 173.76 Million SEK | 8.72% |
| 2020 Q1 | 159.82 Million SEK | 13.83% |
| 2020 Q4 | 196.65 Million SEK | 18.49% |
| 2019 Q3 | 147.47 Million SEK | 1.93% |
| 2019 FY | 140.41 Million SEK | 24.92% |
| 2019 Q4 | 140.41 Million SEK | -4.79% |
| 2019 Q2 | 144.68 Million SEK | 1.75% |
| 2019 Q1 | 142.19 Million SEK | 26.51% |
| 2018 Q4 | 112.4 Million SEK | 10.3% |
| 2018 FY | 112.4 Million SEK | 23.61% |
| 2018 Q1 | 86.99 Million SEK | -4.33% |
| 2018 Q2 | 107.14 Million SEK | 23.16% |
| 2018 Q3 | 101.9 Million SEK | -4.89% |
| 2017 FY | 90.93 Million SEK | 20.67% |
| 2017 Q1 | 73.42 Million SEK | -2.57% |
| 2017 Q2 | 81.54 Million SEK | 11.06% |
| 2017 Q3 | 83.57 Million SEK | 2.49% |
| 2017 Q4 | 90.93 Million SEK | 8.81% |
| 2016 Q4 | 75.35 Million SEK | 31.15% |
| 2016 Q2 | 56.42 Million SEK | 2.51% |
| 2016 FY | 75.35 Million SEK | -57.13% |
| 2016 Q3 | 57.46 Million SEK | 1.84% |
| 2016 Q1 | 55.04 Million SEK | -68.69% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q4 | 175.79 Million SEK | 64.05% |
| 2015 Q3 | 107.15 Million SEK | 0.0% |
| 2015 FY | 175.79 Million SEK | 108.75% |
| 2014 Q4 | 84.21 Million SEK | 0.0% |
| 2014 FY | 84.21 Million SEK | 36.69% |
| 2013 FY | 61.6 Million SEK | 258.3% |
| 2012 FY | 17.19 Million SEK | -77.46% |
| 2011 FY | 76.3 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -678.199% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -4229.138% |
| SQZ Biotechnologies Company | 50.03 Million USD | -728.991% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -472.393% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -602.916% |
| Mesoblast Limited | 188.44 Million USD | -120.128% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -10670.536% |
| Genus plc | 485 Million USD | 14.47% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -6999.879% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -16385.093% |
| Marizyme, Inc. | 26.67 Million USD | -1455.044% |
| ContraFect Corporation | 32.53 Million USD | -1175.15% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -10816.289% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -20836.624% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -10737.439% |
| Intellipharmaceutics International Inc. | 12 Million USD | -3354.301% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -3421.923% |
| MultiCell Technologies, Inc. | 1617.67 USD | -25642892.699% |
| Accustem Sciences Inc. | 1.07 Million USD | -38336.25% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -435.824% |
| EV Biologics, Inc. | 2.11 Million USD | -19512.552% |
| Q BioMed Inc. | 8.13 Million USD | -5000.481% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -400.174% |
| Neon Bloom, Inc. | 1.22 Million USD | -33729.278% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -7960.944% |
| Biomind Labs Inc. | 1.49 Million USD | -27580.213% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -69.957% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -2154.033% |
| Skye Bioscience, Inc. | 14.07 Million USD | -2847.785% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -20536.426% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -291830.751% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -4282.236% |
| IMV Inc. | 37.93 Million USD | -993.563% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -206158.577% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -7119.49% |
| GB Sciences, Inc. | 5.41 Million USD | -7556.938% |
| Alpha Cognition Inc. | 7.16 Million USD | -5689.701% |
| HST Global, Inc. | 593.59 Thousand USD | -69782.731% |
| CSL Limited | 18.62 Billion USD | 97.772% |
| Halberd Corporation | 728.71 Thousand USD | -56824.411% |
| Enzolytics Inc. | 365.26 Million USD | -13.565% |
| Resverlogix Corp. | 67.39 Million USD | -515.495% |
| Affymax, Inc. | 8.87 Million USD | -4576.124% |
| SYBLEU INC | 681.41 Thousand USD | -60776.297% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -49357.872% |
| argenx SE | 444.95 Million USD | 6.772% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -453.683% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -24101.809% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -3384.966% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -11217.884% |
| AVAX Technologies, Inc. | 3.99 Million USD | -10286.717% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1504557.405% |
| Genscript Biotech Corporation | 1.32 Billion USD | 68.713% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -173716.068% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -11008.329% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -60828.068% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -249.403% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -4487.592% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -619689.628% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -28830.21% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -725.281% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -15197.711% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2508.159% |
| ONE Bio Corp. | 27.49 Million USD | -1408.663% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -89166.17% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1512016.794% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -32843.242% |
| Agentix Corp. | 2.51 Million USD | -16423.0% |
| LadRx Corporation | 2.2 Million USD | -18750.885% |
| Cell Source, Inc. | 15.8 Million USD | -2524.322% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -927989.762% |
| Regen BioPharma, Inc. | 5.45 Million USD | -7500.736% |
| Regen BioPharma, Inc. | 5.45 Million USD | -7500.736% |
| NovAccess Global Inc. | 7.86 Million USD | -5177.104% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1576.305% |
| Itoco Inc. | 1.65 Million USD | -24992.626% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -20119.637% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -6757.646% |
| Kadimastem Ltd | 3.5 Million USD | -11735.513% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -98299.072% |
| CytoDyn Inc. | 127.89 Million USD | -224.346% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -992313.694% |
| Mobile Lads Corp. | 1.31 Million USD | -31481.267% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -26382.705% |
| Qrons Inc. | 1.48 Million USD | -27764.269% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -3655.619% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -51188.585% |
| Rebus Holdings, Inc. | 5.24 Million USD | -7813.373% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -6698.188% |
| International Stem Cell Corporation | 5.27 Million USD | -7760.887% |
| Bioxytran, Inc. | 3.24 Million USD | -12665.625% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -66185.24% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -8884.357% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -911.852% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1763.099% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -20380.975% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -7472.453% |
| Neutra Corp. | 973.52 Thousand USD | -42509.825% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1329.671% |
| PureTech Health plc | 125.58 Million USD | -230.315% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -10940.862% |
| IXICO plc | 1.9 Million USD | -21729.224% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1920.649% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -301.474% |
| CSL Limited | 18.62 Billion USD | 97.772% |
| Cellectis S.A. | 249.36 Million USD | -66.347% |